DDrare: Database of Drug Development for Rare Diseases

222. 一次性ネフローゼ症候群
［臨床試験数：234，薬物数：241（DrugBank：78），標的遺伝子数：59，標的パスウェイ数：185］

Searched query = "Primary nephrotic syndrome", "Minimal change nephrotic syndrome", "MCNS", "Membranous nephropathy", "Focal segmental glomerulosclerosis", "FSGS", "Membranoproliferative glomerulonephritis", "MPGN"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 100 mg AP1189; ABATACEPT; ACH-0144471; ACTH; ACTHar; ALXN2040 (ACH-0144471); AP1189; APL-2; AVACOPAN; Abatacept; Acetaminophen; Acetate; Acid mycophenolic (Myfortic); Acthar; Acthar Gel; Adalimumab; Adalimumab (Humira); Adrenocorticotrophic hormone ACTH; Advagraf 0,5mg; Advagraf 1mg; Advagraf 5mg; Aldosterone; Aliskiren; Amoxicillin; Angiotensin; Angiotensin II; Apixaban; Apixaban 5 MG; Aprovel (150 mg); Aprovel 150 mg Tablets; Atorvastatin; Atrasentan; Avacopan; BELIMUMAB; BENLYSTA; BENLYSTA®; BENLYSTA® (belimumab); BMS-188667; Bardoxolone; Bardoxolone methyl; Bardoxolone methyl capsules; Basiliximab; Belimumab; Belimumab 10 mg; Benlysta; Benlysta (belimumab); Bleselumab; CCX140; CCX140-B; CCX168; CDX; CDX-1135; CXA-10; CYCLOPHOSPHAMIDE; Calcium; Chlorambucil; Ciclofosfamida; Ciclosporin; Clarithromycin; Conventional therapy; Corticosteroid; Corticotropin; CsA; CyA; Cyclophosphamide; Cyclophosphamide and steroids; Cyclosporin; Cyclosporin, low dose steroid; Cyclosporine; Cyclosporins; D-Galactose; Dacortín 2,5mg; Dacortín 30mg; Dacortín 5mg; Dalteparin; Danicopan; Danzhu Fuyuan Granule; Dapagliflozin; Daratumumab; Device: LIPOSORBER® LA-15; Device: LIPOSORBER® LA-15 System; Dexamethasone; Diphenhydramine; ECULIZUMAB; ENDOXAN BAXTER*50CPR RIV 50MG; Eculizumab; Eliquis; Enalapril; Endoxan; Evolocumab; Experimental (Non Immunosuppressive Symptomatic Treatment (NIST) and Rituximab); FCM; FG-3019; FK506; Filgotinib; Fluvastatin; Fragmin; Fresolimumab; GC1008; GFB-887; GSK1550188; GSK1550188 (Belimumab); GZ402669; Galactose; Genoxal; Gold; H.P. Acthar Gel; Hydroxychloroquine; INN not available yet; IRBESARTAN; Intravenous (i.v.) methylprednisolone 1000 mg, total 9; Intravenous injection; Irbesartan; Irbesartan tablets; Irbesartan tablets (Approved in the USA. Reference listed drug Avapro) NDC # 43547-0374-03; Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLC; Jianpixiaozhong particles and Wuse Dietotherapy; LA; LNP023; LT4; Lanraplenib; Lansoprazole; Lansoprazole, amoxicillin, clarithromycin; Lisinopril; Lisinopril, losartan, and atorvastatin; Losartan; Losartan Tablets & QingReMoShen Granule; Losmapimod; MABTHERA; MABTHERA*EV 1FL 50ML 500MG; MEDROL*10CPR DIV 4MG; METHYLPREDNISOLONE; MMF; MMF and Dexamethasone; MOR03087; MOR202; MP and CTX; MabThera; MabThera 100 mg concentrate for solution for infusion; MabThera 500 mg concentrate for solution for infusion; Medrol; Mesenchymal stem cells; Methylprednisolone; Methylprednisone; Mizoribine; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF); Mycophenolate mofetil; Mycophenolate mofetil orally 1000 mg twice a day (BID); Mycophenolate mofetil, low dose steroid; Mycophenolate sodium; Mycophenolic acid; Mycophenolic sodium; Myfortic; Myfortic 180mg Tablets; Myfortic 360mg Tablets; Myfortic plus low-dose steroid; Narsoplimab; Neoral; OMS721 (narsoplimab); Obinutuzumab; Oral Cyclosporine; Orencia; Other: D5W; Other: Normal Saline; Over-encapsulated 75 mg Irbesartan Tablets; Over-encapsulated Irbesartan Tablets; PF-06730512; PREDNISOLONE; PREDNISOLONE ACETATE; PREDNISONE; Pegcetacoplan; Pentoxifylline; Perindopril; Pirfenidone; Ponticelli Regimen; Prednisolone; Prednisolone acetate; Prednisolone and chlorambucil; Prednisolone and mycophenolate mofetil; Prednisona; Prednisone; Prednisone 0,5 mg/kg orally on alternate days; Prednisone, FK506, MMF; Prednisone, ciclosporin and mycophenolate mofetil; Procedure: Plasma exchange; Procedure: Plasmapheresis; Prograf; Propagermanium; RE-021; RE-021 (Sparsentan); RITUXIMAB; RTX; Repository Corticotropin Injection; Rituximab; Rituximab Infusion; Rosiglitazone; Rosiglitazone (Avandia); SPARSENTAN; Sirolimus; Soliris; Solondo; Sparsentan; Sparsentan/Over-encapsulated Sparsentan tablet; Sparsentan/Over-encapsulated Sparsentan tablets; Steroid & Cyclosporin; Sulfate; Symptomatic treatment (Converting Enzyme inhibitor, Angiotensin II, Anti-renin, Aldosterone antagonist diuretic, Beta blocker, Calcium inhibitor, statin); Synacthen Depot; Synacthen Depot 1mg; TACROLIMUS; TRU-015; TRUXIMA; TRUXIMAB; TW; Tacrolimus; Tacrolimus Capsules; Tacrolimus combined with prednisone; Tetracosactide; Tetracosactide hexacetaat; The Comprehensive Treatment Regimen of Traditional Chinese Medicine; The immunosuppressive agents; Tripterygium; Tripterygium Wilfordii; Tripterygium wilfordii; Tripterygium wilfordii (TW); Truxima; URBASON*IM EV 1F 250MG+1F 5ML; Urbason; VB119; VX-147; VX147; Valproic Acid; Valproic acid; Valsartan; Vitamin D; Voclosporin; Zestril; [CCX140-B];  LNP023 HYDROCHLORIDE SALT

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01613118 (ClinicalTrials.gov)	December 2013	4/6/2012	Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis	Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study	Focal Segmental Glomerulosclerosis	Drug: RE-021 (Sparsentan);Drug: Irbesartan	Travere Therapeutics, Inc.	NULL	Active, not recruiting	8 Years	75 Years	All	100	Phase 2	United States;Belgium;Czechia;Italy;Czech Republic

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT01613118
(ClinicalTrials.gov)

December 2013

4/6/2012

Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis

Efficacy and Safety of RE-021, a Dual Endothelin Receptor and Angiotensin Receptor Blocker, in Patients With Focal Segmental Glomerulosclerosis (FSGS): a Randomized, Double-Blind, Active-Control, Dose-Escalation Study

Focal Segmental Glomerulosclerosis

Drug: RE-021 (Sparsentan);Drug: Irbesartan

Travere Therapeutics, Inc.

NULL

Active, not recruiting

8 Years

75 Years

All

100

Phase 2

United States;Belgium;Czechia;Italy;Czech Republic